Magnus Backlund

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.

Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.

Journal: Journal of the National Cancer Institute

Published: September 30, 2025

Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.

Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.

Journal: Breast cancer research : BCR

Published: September 21, 2024

Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.

Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.

Journal: Journal of the National Cancer Institute

Published: April 17, 2024

Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp).

Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp).

Journal: BMC health services research

Published: February 08, 2024

Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.

Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.

Journal: British journal of cancer

Published: February 24, 2023

Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.

Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.

Journal: International journal of cancer

Published: August 26, 2022

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 06, 2021

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 18, 2021

Time to Mammographic Density Decrease After Exposure to Tamoxifen.

Time to Mammographic Density Decrease After Exposure to Tamoxifen.

Journal: The oncologist

Published: November 20, 2020

Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.

Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.

Journal: The oncologist

Published: November 20, 2020

Hormonal determinants of mammographic density and density change.

Hormonal determinants of mammographic density and density change.

Journal: Breast cancer research : BCR

Published: January 14, 2020

Ra-223 DICHLORIDE: Hp(0.07) RATE ASSESSMENT FROM UNSHIELDED SYRINGES.

Ra-223 DICHLORIDE: Hp(0.07) RATE ASSESSMENT FROM UNSHIELDED SYRINGES.

Journal: Radiation protection dosimetry

Published: June 05, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026